DOC vs VTR

For growth investors, Ventas, Inc.

(VTR) is the stronger pick with 18. 5% revenue growth year-over-year, versus 4. 5% for Healthpeak Properties, Inc. (DOC). Ventas, Inc. (VTR) offers the better valuation at 160. 4x trailing P/E (118. 1x forward), making it the more compelling value choice. Analysts rate Healthpeak Properties, Inc. (DOC) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Ventas, Inc.

(VTR) is the cheapest at 160. 4x versus Healthpeak Properties, Inc. at 195. 0x. On forward P/E, Healthpeak Properties, Inc. is actually cheaper at 100. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ventas, Inc.

(VTR) delivered a total return of +77. 4%, compared to -16. 1% for Healthpeak Properties, Inc. (DOC). Over 10 years, the gap is even starker: VTR returned +66. 5% versus DOC's +15. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ventas, Inc.

(VTR) is the lower-risk stock at 0. 01β versus Healthpeak Properties, Inc. 's 0. 52β — meaning DOC is approximately 5359% more volatile than VTR relative to the S&P 500. On balance sheet safety, Ventas, Inc. (VTR) carries a lower debt/equity ratio of 105% versus 126% for Healthpeak Properties, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ventas, Inc.

(VTR) is pulling ahead at 18. 5% versus 4. 5% for Healthpeak Properties, Inc. (DOC). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -72. 2% for Healthpeak Properties, Inc.. Over a 3-year CAGR, VTR leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ventas, Inc.

(VTR) is the more profitable company, earning 4. 3% net margin versus 2. 5% for Healthpeak Properties, Inc. — meaning it keeps 4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOC leads at 19. 3% versus 14. 2% for VTR. At the gross margin level — before operating expenses — DOC leads at 22. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Healthpeak Properties, Inc.

(DOC) trades at 100. 1x forward P/E versus 118. 1x for Ventas, Inc. — 18. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VTR: 4. 8% to $90. 80.

All stocks in this comparison pay dividends.

Healthpeak Properties, Inc. (DOC) offers the highest yield at 6. 3%, versus 2. 1% for Ventas, Inc. (VTR).

For long-horizon retirement investors, Ventas, Inc.

(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Both have compounded well over 10 years (VTR: +66. 5%, DOC: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DOC is a mid-cap income-oriented stock; VTR is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.